CT chest, abdomen and pelvis

DIAGNOSTIC_TEST2 trials

Conditions

Advanced Solid TumorEGFR-Mutated Non-Small-Cell Lung CarcinomaMetastatic Castration-resistant Prostate CancerNon-metastatic Castration-resistant Prostate CancerProstate CancerProstate NeoplasmSmall Cell/NeuroendocrineSolid Tumor

Phase 1

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

CompletedNCT03493945

National Cancer Institute (NCI)Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer +3

Start: 2018-05-01End: 2024-10-08Updated: 2025-09-30

Phase 2

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

TerminatedNCT04538378

National Cancer Institute (NCI)EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine

Start: 2021-07-07End: 2024-02-27Updated: 2025-01-27

Cancer Immunology Research2026-02-18

582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer

Regular and Young Investigator Award Abstracts2021-11-012 citations

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer

Journal for ImmunoTherapy of Cancer2021-09-0136 citations

Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.

Journal of Clinical Oncology2019-05-20

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Journal for ImmunoTherapy of Cancer2018-09-1858 citations

CT chest, abdomen and pelvis

Sponsors

Conditions

Phase 1

Phase 2

Related Papers